AL4631
Type 2 Diabetes
Phase IIActive
Key Facts
About Shanghai Allist Pharmaceuticals
Shanghai Allist Pharmaceuticals, founded in 2004, is a publicly traded biopharmaceutical innovator with a mission to leverage technology for improving patient lives. The company has successfully transitioned from a research organization to an integrated enterprise with a focus on kinase inhibitors for oncology and drugs for metabolic diseases, culminating in a high-profile IPO on the Shanghai STAR Market. Its strategy centers on advancing a deep clinical pipeline, capitalizing on China's supportive innovation policies, and pursuing global partnerships to maximize the value of its novel therapeutics.
View full company profileTherapeutic Areas
Other Type 2 Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| Diabetes Management Gel | Gelteq Limited | Formulation Development |
| Tolimidone | Biodexa Pharmaceuticals | Phase 2 |
| Generic Semaglutide Injection (Obeda) | Dr. Reddy's Laboratories | Approved |
| BioChaperone® Lispro | Adocia | Phase 3 |
| BioChaperone® Combo (Insulin Glargine / Lixisenatide) | Adocia | Phase 2 |
| AJN003 (LuCI™) | AltrixBio | Pre-clinical |
| Hepatic Denervation for Type 2 Diabetes | Metavention | Feasibility |
| MVD-1 (SANA) | Eolo Pharma | Discovery |
| V-Go | MannKind | Approved |
| Type 2 Diabetes Management | iWel | Development |
| Band-assisted Duodenal Mucosal Resurfacing (DMR) | Endolastic | Pre-clinical |
| REMD-477 (Volagidemab) | REMD Biotherapeutics | Phase 2 (completed) |